首页> 外文期刊>International journal of hematology >Prognosis of mature T cell lymphoma is poorer than that of diffuse large B cell lymphoma in IPI low-risk group, but not in intermediate- and high-risk groups
【24h】

Prognosis of mature T cell lymphoma is poorer than that of diffuse large B cell lymphoma in IPI low-risk group, but not in intermediate- and high-risk groups

机译:在IPI低危组中,成熟T细胞淋巴瘤的预后要比弥散性大B细胞淋巴瘤的预后要差,但在中危和高危组中则没有

获取原文
获取原文并翻译 | 示例
       

摘要

Mature T cell lymphoma has been noted for poor prognosis when compared with B cell lymphoma, even in the pre-rituximab era. To confirm this difference, a retrospective cohort study was conducted. One hundred-and nineteen patients with mature T cell lymphoma and 568 patients with diffuse large B cell lymphoma (DLBCL) who did not receive rituximab as first induction were studied. Overall survival (OS) was worse for patients with international prognostic index (IPI) scores indicating low-risk mature T cell lymphoma than for those with DLBCL (3-year OS 87 % vs. 58 %, P = 0.001), but not in other risk groups. Prognosis of mature T cell lymphoma was significantly poorer in the IPI low-risk group, as compared with DLBCL. ? 2012 The Japanese Society of Hematology.
机译:与B细胞淋巴瘤相比,即使在利妥昔单抗时代,成熟的T细胞淋巴瘤的预后也很差。为了证实这种差异,进行了一项回顾性队列研究。研究了119例未接受利妥昔单抗作为首次诱导的成熟T细胞淋巴瘤患者和568例弥漫性大B细胞淋巴瘤(DLBCL)患者。具有国际预后指数(IPI)评分表明低危成熟T细胞淋巴瘤的患者的总生存(OS)比患有DLBCL的患者更差(3年OS 87%vs.58%,P = 0.001)其他风险组。与DLBCL相比,IPI低危组的成熟T细胞淋巴瘤的预后明显较差。 ? 2012年日本血液学会。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号